Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial
MT Newswires Live
Jul 16
Greenwich LifeSciences (GLSI) said Thursday the European Medicines Agency has approved the enrollment of both HLA-A*02 and non-HLA-A*02 patients in a phase 3 trial evaluating GLSI-100 in preventing breast cancer recurrences.
The company said all 170 to 180 clinical trial sites in the US and Europe are now operating under the same protocol and are enrolling both HLA populations.
Greenwich said it was still awaiting feedback from UK and Canadian regulators and that it now has a pathway to pursue approval of its investigational immunotherapy for both HLA populations.
Shares of the company were up more than 5% in premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.